-+ 0.00%
-+ 0.00%
-+ 0.00%

ProMIS Neurosciences To Highlight Data On ALS & Parkinsons Disease Programs At AD/PD 2026 International Conference

Benzinga·03/18/2026 12:03:58
Listen to the news

ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that it will present two scientific posters at the Alzheimer's & Parkinson's Diseases Conference (AD/PD™ 2026), being held March 17–21, 2026 in Copenhagen, Denmark.

The posters will highlight ongoing research related to the Company's proprietary discovery platform and its approach to selectively targeting toxic misfolded proteins in neurodegenerative diseases.